Pulmonary Fibrosis
Conditions
Brief summary
KL-6 may be a useful biomarker in patients with interstitial lung disease, but there is limited information in non-Asian populations. Therefore, it is necessary to carry out studies in other populations to confirm the diagnostic values of the biomarker and its prognostic implication. Hypothesis KL-6 may be a useful biomarker in the management of interstitial lung diseases. But it is necessary to know more about its utility in the European population. Study Objectives: * To determine the concentration of KL-6 in serum of patients with pulmonary fibrosis at the time of diagnosis compared to patients without pulmonary fibrosis * Diagnostic yield of KL-6 in patients with pulmonary fibrosis. * Correlation of KL-6 values with functional and radiological parameters of disease severity at diagnosis. * Correlation of serum KL-6 values with the evolution of the disease.
Interventions
DIAGNOSTIC_TESTKL-6 levels
Measure of KL-6 in serum
Sponsors
Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Study design
Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Subjects older than 18 years. 2. Chronic respiratory diseases )including Fibrotic interstitial lung disease, asthma or COPD) related or not to a connective tissue disease. 3. Acceptance of the patient to participate in the study by signing the informed consent after having discussed with the researchers the objectives, risks and potential benefits.
Exclusion criteria
1. Absence of informed consent 2. Psychiatric disorder or limitation of collaboration (including language, socio-cultural problem, etc.).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Serum KL-6 levels in patients with pulmonary fibrosis at the time of diagnosis. | Baseline |
Countries
Spain
Outcome results
None listed